The global Oncology Targeted Therapy market size was valued at US$ 63450 million in 2024 and is forecast to a readjusted size of USD 115840 million by 2031 with a CAGR of 9.1% during review period.
Targeted therapy is听a type of cancer treatment that uses drugs or other substances to precisely identify and attack certain types of cancer cells. A targeted therapy can be used by itself or in combination with other treatments, such as traditional or standard chemotherapy, surgery, or radiation therapy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Oncology Targeted Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oncology Targeted Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
Global Oncology Targeted Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Oncology Targeted Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Oncology Targeted Therapy market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oncology Targeted Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oncology Targeted Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, AstraZeneca, Novartis, Roche, Bristol-Myers Squibb, Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Oncology Targeted Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Sorafenib
Lenvatinib
Regorafenib
Osimertinib
Anlotinib
Alectinib
Other
麻豆原创 segment by Application
Hospital
Retail Pharmacy
Other
麻豆原创 segment by players, this report covers
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
AstraZeneca
Novartis
Roche
Bristol-Myers Squibb
Pfizer
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncology Targeted Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncology Targeted Therapy, with revenue, gross margin, and global market share of Oncology Targeted Therapy from 2020 to 2025.
Chapter 3, the Oncology Targeted Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Oncology Targeted Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Targeted Therapy.
Chapter 13, to describe Oncology Targeted Therapy research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Oncology Targeted Therapy by Type
1.3.1 Overview: Global Oncology Targeted Therapy 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Oncology Targeted Therapy Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Sorafenib
1.3.4 Lenvatinib
1.3.5 Regorafenib
1.3.6 Osimertinib
1.3.7 Anlotinib
1.3.8 Alectinib
1.3.9 Other
1.4 Global Oncology Targeted Therapy 麻豆原创 by Application
1.4.1 Overview: Global Oncology Targeted Therapy 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Oncology Targeted Therapy 麻豆原创 Size & Forecast
1.6 Global Oncology Targeted Therapy 麻豆原创 Size and Forecast by Region
1.6.1 Global Oncology Targeted Therapy 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Oncology Targeted Therapy 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Oncology Targeted Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Oncology Targeted Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Oncology Targeted Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Oncology Targeted Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Oncology Targeted Therapy 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Oncology Targeted Therapy Product and Solutions
2.1.4 Bayer Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Oncology Targeted Therapy Product and Solutions
2.2.4 Eisai Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Eisai Recent Developments and Future Plans
2.3 Zelgen
2.3.1 Zelgen Details
2.3.2 Zelgen Major Business
2.3.3 Zelgen Oncology Targeted Therapy Product and Solutions
2.3.4 Zelgen Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Zelgen Recent Developments and Future Plans
2.4 Cipla
2.4.1 Cipla Details
2.4.2 Cipla Major Business
2.4.3 Cipla Oncology Targeted Therapy Product and Solutions
2.4.4 Cipla Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Cipla Recent Developments and Future Plans
2.5 Natco Pharma
2.5.1 Natco Pharma Details
2.5.2 Natco Pharma Major Business
2.5.3 Natco Pharma Oncology Targeted Therapy Product and Solutions
2.5.4 Natco Pharma Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Natco Pharma Recent Developments and Future Plans
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca Oncology Targeted Therapy Product and Solutions
2.6.4 AstraZeneca Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 AstraZeneca Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Oncology Targeted Therapy Product and Solutions
2.7.4 Novartis Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Roche
2.8.1 Roche Details
2.8.2 Roche Major Business
2.8.3 Roche Oncology Targeted Therapy Product and Solutions
2.8.4 Roche Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Roche Recent Developments and Future Plans
2.9 Bristol-Myers Squibb
2.9.1 Bristol-Myers Squibb Details
2.9.2 Bristol-Myers Squibb Major Business
2.9.3 Bristol-Myers Squibb Oncology Targeted Therapy Product and Solutions
2.9.4 Bristol-Myers Squibb Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Oncology Targeted Therapy Product and Solutions
2.10.4 Pfizer Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Pfizer Recent Developments and Future Plans
2.11 BEACON Pharma
2.11.1 BEACON Pharma Details
2.11.2 BEACON Pharma Major Business
2.11.3 BEACON Pharma Oncology Targeted Therapy Product and Solutions
2.11.4 BEACON Pharma Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 BEACON Pharma Recent Developments and Future Plans
2.12 Jiangxi Shanxiang
2.12.1 Jiangxi Shanxiang Details
2.12.2 Jiangxi Shanxiang Major Business
2.12.3 Jiangxi Shanxiang Oncology Targeted Therapy Product and Solutions
2.12.4 Jiangxi Shanxiang Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Jiangxi Shanxiang Recent Developments and Future Plans
2.13 Yao Pharma
2.13.1 Yao Pharma Details
2.13.2 Yao Pharma Major Business
2.13.3 Yao Pharma Oncology Targeted Therapy Product and Solutions
2.13.4 Yao Pharma Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Yao Pharma Recent Developments and Future Plans
2.14 CSPC
2.14.1 CSPC Details
2.14.2 CSPC Major Business
2.14.3 CSPC Oncology Targeted Therapy Product and Solutions
2.14.4 CSPC Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 CSPC Recent Developments and Future Plans
2.15 CHIATAI Tianqing
2.15.1 CHIATAI Tianqing Details
2.15.2 CHIATAI Tianqing Major Business
2.15.3 CHIATAI Tianqing Oncology Targeted Therapy Product and Solutions
2.15.4 CHIATAI Tianqing Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 CHIATAI Tianqing Recent Developments and Future Plans
2.16 Simcere
2.16.1 Simcere Details
2.16.2 Simcere Major Business
2.16.3 Simcere Oncology Targeted Therapy Product and Solutions
2.16.4 Simcere Oncology Targeted Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Simcere Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Oncology Targeted Therapy Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Oncology Targeted Therapy by Company Revenue
3.2.2 Top 3 Oncology Targeted Therapy Players 麻豆原创 Share in 2024
3.2.3 Top 6 Oncology Targeted Therapy Players 麻豆原创 Share in 2024
3.3 Oncology Targeted Therapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 Oncology Targeted Therapy 麻豆原创: Region Footprint
3.3.2 Oncology Targeted Therapy 麻豆原创: Company Product Type Footprint
3.3.3 Oncology Targeted Therapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Oncology Targeted Therapy Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Oncology Targeted Therapy 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Oncology Targeted Therapy Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Oncology Targeted Therapy 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Oncology Targeted Therapy Consumption Value by Type (2020-2031)
6.2 North America Oncology Targeted Therapy 麻豆原创 Size by Application (2020-2031)
6.3 North America Oncology Targeted Therapy 麻豆原创 Size by Country
6.3.1 North America Oncology Targeted Therapy Consumption Value by Country (2020-2031)
6.3.2 United States Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Oncology Targeted Therapy Consumption Value by Type (2020-2031)
7.2 Europe Oncology Targeted Therapy Consumption Value by Application (2020-2031)
7.3 Europe Oncology Targeted Therapy 麻豆原创 Size by Country
7.3.1 Europe Oncology Targeted Therapy Consumption Value by Country (2020-2031)
7.3.2 Germany Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Oncology Targeted Therapy Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Oncology Targeted Therapy Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Oncology Targeted Therapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific Oncology Targeted Therapy Consumption Value by Region (2020-2031)
8.3.2 China Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Oncology Targeted Therapy Consumption Value by Type (2020-2031)
9.2 South America Oncology Targeted Therapy Consumption Value by Application (2020-2031)
9.3 South America Oncology Targeted Therapy 麻豆原创 Size by Country
9.3.1 South America Oncology Targeted Therapy Consumption Value by Country (2020-2031)
9.3.2 Brazil Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Oncology Targeted Therapy Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Oncology Targeted Therapy Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Oncology Targeted Therapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa Oncology Targeted Therapy Consumption Value by Country (2020-2031)
10.3.2 Turkey Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Oncology Targeted Therapy 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Oncology Targeted Therapy 麻豆原创 Drivers
11.2 Oncology Targeted Therapy 麻豆原创 Restraints
11.3 Oncology Targeted Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Oncology Targeted Therapy Industry Chain
12.2 Oncology Targeted Therapy Upstream Analysis
12.3 Oncology Targeted Therapy Midstream Analysis
12.4 Oncology Targeted Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
AstraZeneca
Novartis
Roche
Bristol-Myers Squibb
Pfizer
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
听
听
*If Applicable.
